AVITA Medical (AVMXY.OB) on Monday announced that the FDA has approved the company's Investigational Device Exemption (IDE) application to conduct a study of the Autologous Cell Harvesting Device RECELL in combination with meshed autografting for the treatment of acute soft tissue injuries, defects, and reconstruction.
from RTT - Biotech https://ift.tt/32KH64R
via IFTTT
No comments:
Post a Comment